NASDAQ:CYNA

CYNA (CYNA) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$40.48
$40.48
50-Day Range
N/A
52-Week Range
$10.54
$40.67
Volume
N/A
Average Volume
113,889 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CYNA stock logo

About CYNA Stock (NASDAQ:CYNA)

Cynapsus Therapeutics Inc is a Canada-based specialty central nervous system (CNS) pharmaceutical company. It develops a sublingual thin film for the potential treatment for on-demand management of debilitating OFF episodes associated with Parkinson’s disease (PD). The Company completed a Phase two clinical trial for its product candidate, APL-130277, a sublingual formulation of apomorphine hydrochloride, or apomorphine. Apomorphine is the only molecule approved for acute, intermittent treatment of OFF episodes for advanced PD patients, but is currently only approved as a subcutaneous injection in the United States. APL-130277 is a turning ON medication designed to convert a PD patient from the OFF to the ON state while avoiding the issues associated with subcutaneous delivery of apomorphine. It is designed to convert all types of OFF episodes, including morning OFF episodes. Furthermore, the Company has initiated its pivotal Phase three clinical program for APL-130277.

CYNA Stock News Headlines

[Shocking] Elon Musk’s Plan To End Banks
Leaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030.
[Shocking] Elon Musk’s Plan To End Banks
Leaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030.
Juanita Mary Martha 'Corky' (Corbett) Swartout
Troy Police Department blotter
Ababa pounds out superb 69, leads by 4
See More Headlines
Receive CYNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CYNA and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/10/2016
Today
4/22/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:CYNA
Previous Symbol
OTCMKTS:CYNAF
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

CYNA Stock Analysis - Frequently Asked Questions

How were CYNA's earnings last quarter?

CYNA (NASDAQ:CYNA) released its quarterly earnings results on Wednesday, August, 10th. The biotechnology company reported ($0.83) earnings per share for the quarter, missing analysts' consensus estimates of ($0.77) by $0.06.

What other stocks do shareholders of CYNA own?
When did CYNA IPO?

CYNA (CYNA) raised $64 million in an IPO on Thursday, June 18th 2015. The company issued 4,500,000 shares at a price of $14.18 per share. BofA Merrill Lynch served as the underwriter for the IPO and Nomura and Noble Life Science Partners were co-managers.

This page (NASDAQ:CYNA) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners